Latest studies
- Recruiting
Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation
This study looks back at information from hospitals to understand serious problems that can happen during or soon after a heart procedure called ablation for fast or extra heartbeats (VT/PVC). Researchers want to find out why these problems occur and how they were managed.
Ventricular Tachycardia (VT)Premature Ventricular ComplexesSwitzerland - Recruiting
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
This study looks at a special treatment for liver cancer or cancer that has spread to the liver. It's called PVE/HVE and aims to help the liver grow bigger before surgery. Researchers are gathering information from many hospitals to see how well it works and if it's safe.
Liver CancerLiver MetastasesSwitzerland - Recruiting
Total Shoulder Arthroplasty Multi-Center Registry
This study looks at how well different types of shoulder replacement surgery work over time. It collects information from many patients in different hospitals who are having either an 'anatomic' or 'reverse' shoulder replacement to help doctors understand the best ways to treat shoulder problems and improve patient results.
Shoulder ArthroplastySwitzerland - Not yet recruiting
Tracheostomy Practice in Adult Intensive Care Units
This study looks at how tracheostomies are used and managed in adult intensive care units (ICU) around the world. It aims to understand current practices, identify differences, and find ways to improve care and safety for patients with a tracheostomy.
Tracheostomy PatientsTracheostomy DecannulationIntensive Care (ICU)Switzerland - RecruitingPHASE2, PHASE3
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
This study is testing a new medicine, alpelisib, for children and adults with lymphatic malformations caused by a specific gene change (PIK3CA mutation). It will compare alpelisib to a dummy medicine to see if it can shrink the malformations and reduce symptoms.
Lymphatic MalformationsSwitzerland - Active not recruitingPHASE2
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
This study is looking at a new medicine called ALN-APP for a condition called Cerebral Amyloid Angiopathy (CAA). It aims to see how well ALN-APP works to slow down CAA and if it's safe. Participants will either receive the new medicine or a dummy treatment.
Cerebral Amyloid AngiopathySwitzerland - RecruitingPHASE2
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
This study looks at how well a medicine called alpelisib works for children and adults with a condition called PROS, which causes parts of the body to grow too much. It also checks if the medicine is safe and how it moves through the body.
PIK3CA-related Overgrowth Spectrum (PROS)Switzerland - Recruiting
Product Surveillance Registry
This study keeps track of how well Medtronic medical devices, like those for heart problems or other conditions, work in real life. It aims to make sure these devices are safe and effective for patients.
Cardiac Rhythm DisordersUrological DisordersNeurological DisordersCardiovascular DisordersSwitzerland - RecruitingPHASE3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
This study looks at a new medicine called survodutide for adults with a liver condition called NASH or MASH and scarring (cirrhosis). Participants will get either the medicine or a dummy treatment, along with diet and exercise advice, to see if it helps their liver.
Metabolic Dysfunction Associated SteatohepatitisSwitzerland - RecruitingPHASE2, PHASE3
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
This study keeps an eye on people who have had a special treatment called gene-modified T-cell therapy for cancer. It aims to check their health and how well the treatment worked over a long time, making sure it's safe and effective.
NeoplasmsSwitzerland - Active not recruitingPHASE1, PHASE2
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
This study looks at new drug combinations for advanced ER+ breast cancer in women aged 18-100. It tests LEE011 and BYL719 with letrozole to find safe and effective doses, hoping to improve treatment for this type of cancer.
Breast CancerSwitzerland - Not yet recruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
This study looks at a new treatment called BMS-986353 for severe Systemic Sclerosis. It compares this new treatment with standard care to see if it's more effective and safe for people with this condition.
Systemic SclerosisSwitzerland - RecruitingNA
The Fourth Left Atrial Appendage Occlusion Study
This study looks at whether a 'WATCHMAN device' can prevent strokes in people with atrial fibrillation who are already taking blood thinners but still have a high stroke risk. It aims to see if blocking off a small part of the heart called the left atrial appendage helps.
Atrial FibrillationStroke, IschemicSystemic EmbolismSwitzerland - RecruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
This study looks at a new drug, Nizubaglustat, for Niemann-Pick Type C (NPC) disease in children and young people. It aims to see if the drug can help with movement problems and if it's safe, compared to a dummy pill.
Niemann-Pick Type C DiseaseSwitzerland - RecruitingPHASE3
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
This study looks at the long-term safety of a medicine called inclisiran for people aged 12-100 with high cholesterol due to a genetic condition (HeFH or HoFH). It's for those who have already been in earlier inclisiran studies.
Heterozygous or Homozygous Familial HypercholesterolemiaSwitzerland - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisSwitzerland - RecruitingPHASE2, PHASE3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
This study is looking for better treatments for a common eye condition called wet macular degeneration. Researchers want to see if a new medicine, tiespectus, works as well as an existing treatment, aflibercept. It's for people recently diagnosed with this condition.
Macular DegenerationAge-Related Macular DegenerationChoroidal NeovascularizationWet Macular DegenerationSwitzerland - RecruitingPHASE3
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
This study compares Elritercept with Epoetin Alfa for adults with a certain type of Myelodysplastic Syndrome (MDS) and anaemia. It checks if Elritercept reduces the need for blood transfusions and improves tiredness, while also looking at safety.
Myelodysplastic SyndromeAnemiaSwitzerland - RecruitingPHASE1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
This study is looking at a new medicine called Inno8 for people with haemophilia A. Its main goal is to check how different amounts of the medicine work and if it's safe. It's a short study lasting about 11 weeks.
Haemophilia ASwitzerland - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
This study is comparing two medicines, fenebrutinib and ocrelizumab, to see which is safer and better at slowing down primary progressive multiple sclerosis (PPMS). It's for adults with PPMS and aims to understand how these treatments affect the disease progression.
Multiple Sclerosis, Primary ProgressiveSwitzerland - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesSwitzerland - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseSwitzerland - RecruitingPHASE2
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
This study is testing a new medicine, efgartigimod, for adults with systemic sclerosis. It aims to see if the medicine helps improve symptoms and if it's safe, compared to a dummy medicine. We're looking for people to join for about 15 months.
Systemic Sclerosis (SSc)Switzerland - RecruitingPHASE3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
This study looks at a new medicine called survodutide for adults with a liver condition called MASH and moderate to advanced liver damage. It aims to see if the medicine can improve liver health and how safe it is.
Metabolic Dysfunction Associated Steatohepatitis (MASH)Liver FibrosisSwitzerland - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
This study compares a new medicine, empasiprubart, with standard IVIg treatment for adults with CIDP. It looks at how well they work and if they are safe. Participants will receive one of these treatments, or a dummy treatment, for several months.
Chronic Inflammatory Demyelinating PolyneuropathyCIDPCIDP - Chronic Inflammatory Demyelinating PolyneuropathySwitzerland - RecruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This study looks at a new drug combination, sacituzumab tirumotecan and pembrolizumab, for a type of breast cancer called triple-negative. It's for patients who had initial treatment but still have some cancer cells after surgery. We want to see if this new combination helps prevent the cancer from coming back better than standard care.
Triple-Negative Breast CancerSwitzerland - RecruitingPHASE3
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
This study is for women with advanced ovarian cancer that has responded well to initial treatment. It's testing a new medicine called sac-TMT, sometimes with bevacizumab, to see if it can keep the cancer from growing or coming back for longer than standard care.
Ovarian NeoplasmsOvarian CancerSwitzerland - RecruitingPHASE3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
This study is testing a new medicine, nerandomilast, for people with systemic sclerosis. It aims to see if the medicine can improve symptoms and slow the disease. Adults with systemic sclerosis might be able to join this study.
Systemic SclerosisSwitzerland - Active not recruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusSwitzerland - RecruitingPHASE3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
This study is testing a new medicine, ifinatamab deruxtecan (I-DXd), for men with advanced prostate cancer that has spread and isn't responding to hormone therapy. We want to see if I-DXd helps men live longer and keeps their cancer from growing compared to standard chemotherapy.
Prostate CancerProstatic NeoplasmsSwitzerland - RecruitingPHASE1, PHASE2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
This study looks at a new drug, sacituzumab tirumotecan, alone or with other common treatments for advanced bowel, pancreatic, and bile duct cancers. Researchers want to see if it's safe, tolerable, and can shrink these cancers.
Colorectal CancerPancreatic Ductal AdenocarcinomaBiliary Tract CancerSwitzerland - RecruitingPHASE3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
This study looks at a new medicine, BI 764198, for people aged 12 and over with a kidney condition called FSGS. It aims to see if this medicine helps improve kidney health. Participants will take a tablet daily and have their kidney function checked regularly.
Focal Segmental GlomerulosclerosisSwitzerland - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study is looking at a new treatment for non-small cell lung cancer after surgery. It combines two medicines, sacituzumab tirumotecan and pembrolizumab, to see if they work better together than pembrolizumab alone in preventing the cancer from coming back.
Non Small Cell Lung CancerSwitzerland - RecruitingPHASE3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This study looks at a new medicine, Maridebart cafraglutide, for people with heart failure and obesity. It aims to see if the medicine can reduce heart-related problems like hospital stays, improve symptoms, and help people live longer, alongside their usual heart failure care.
Heart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection FractionObesitySwitzerland - RecruitingPHASE2
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
This study looks at whether a new medicine, BI 764198, can help adults and teenagers with certain kidney problems. It compares the new medicine to a dummy pill to see if it reduces protein in the urine and improves kidney health.
Proteinuric Kidney DiseasesSwitzerland - Active not recruitingPHASE4
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
This study looks at how a new medicine, mavacamten, affects the heart's structure in adults with a specific heart condition called hypertrophic cardiomyopathy. We'll use special MRI scans to see these changes, aiming to better understand the treatment's impact.
Cardiomyopathy, HypertrophicSwitzerland - RecruitingPHASE2
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
This study looks at a new combination treatment for advanced bowel cancer that has spread. It combines a new drug, VVD-133214, with an existing immunotherapy, pembrolizumab. The aim is to see if this combination works better than pembrolizumab alone for certain types of bowel cancer.
Colorectal AdenocarcinomaSwitzerland - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesSwitzerland - Recruiting
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
The RIETE study is building a large database of information from patients with blood clots (venous thromboembolism). It helps doctors better understand and treat patients, especially those with other health problems, to improve care and understand what medicine works best for different groups.
Venous ThromboembolismSwitzerland - RecruitingPHASE3
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
This study is testing a new medicine, cladribine, in pill form for people with a muscle weakening condition called myasthenia gravis. We want to see if it helps and if it's safe compared to a dummy pill. We're also looking at its long-term effects and how the body uses the medicine.
Generalized Myasthenia GravisSwitzerland - RecruitingPHASE3
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
This study looks at how safe a new medicine called finerenone is for children and young people (aged 1-18) with long-term kidney disease, when taken with other common kidney medicines. It also checks if it helps reduce protein in their urine.
Chronic Kidney DiseaseProteinuriaChildrenSwitzerland - RecruitingPHASE3
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
This study looks at a new medicine called mezagitamab for a kidney problem called IgA nephropathy. It compares mezagitamab to a dummy medicine to see if it lowers protein in the urine and helps protect kidneys. All adults over 18 with this condition can take part.
Kidney DiseaseSwitzerland - RecruitingPHASE3
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
This study looks at a new medicine, nerandomilast, for people with lung scarring (fibrosis) linked to rheumatic diseases. It aims to see if nerandomilast improves lung function when standard treatments haven't helped. Participants take tablets for several months, with regular check-ups.
Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung DiseasesSwitzerland - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerSwitzerland - RecruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
This study is looking at a new medicine called AZ-3102 for children and young people with rare conditions like Niemann-Pick Type C, GM1 Gangliosidosis, or GM2 Gangliosidosis. It aims to see if the medicine is safe and if it helps improve their health over 18 months.
Niemann-Pick Type C DiseaseGM1 GangliosidosisGM2 GangliosidosisSwitzerland - RecruitingPHASE2
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
This study is testing a new medicine, Vamifeport, for people with a common type of iron overload called hereditary hemochromatosis. It aims to see if the medicine can reduce the amount of iron stored in the liver. Two groups will be compared: one getting the medicine and one getting a dummy pill.
Homeostatic Iron Regulator Gene-related Hereditary HemochromatosisSwitzerland - RecruitingPHASE3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
This study is testing a new medicine, nucresiran, for people with a heart condition called transthyretin amyloidosis cardiomyopathy. Doctors want to see if it can improve health, reduce heart-related problems, and make patients feel better compared to a dummy medicine.
Transthyretin Amyloidosis With CardiomyopathySwitzerland - RecruitingPHASE3
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
This study is testing a new medicine called Nucresiran for people with hereditary transthyretin amyloidosis (hATTR) that affects their nerves. It aims to see how well the medicine works compared to current treatments to improve nerve problems, quality of life, and reduce the level of a harmful protein in the blood.
Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyhATTR-PNSwitzerland - Active not recruitingPHASE2
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
This study is testing a new use for olaparib, a medicine to treat advanced cancers that have specific gene changes. It's for people whose cancer hasn't responded to usual treatments and has gene faults linked to how cells repair themselves.
Advanced Solid NeoplasmsSwitzerland - RecruitingPHASE3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This study looks at a new combination of drugs, adagrasib, pembrolizumab, and chemotherapy, for people with a specific type of advanced non-small cell lung cancer (NSCLC) that hasn't been treated before and has a KRAS G12C gene change.
Carcinoma, Non-Small-Cell LungSwitzerland